Vanguard Personalized Indexing Management LLC Acquires 9,928 Shares of 10x Genomics $TXG

Vanguard Personalized Indexing Management LLC lifted its holdings in 10x Genomics (NASDAQ:TXG) by 81.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,141 shares of the company’s stock after acquiring an additional 9,928 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in 10x Genomics were worth $256,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in TXG. GAMMA Investing LLC grew its stake in shares of 10x Genomics by 81.8% in the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock valued at $31,000 after buying an additional 1,614 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in shares of 10x Genomics by 9.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 31,061 shares of the company’s stock valued at $271,000 after buying an additional 2,564 shares during the period. Diversified Trust Co grew its stake in shares of 10x Genomics by 60.8% in the 1st quarter. Diversified Trust Co now owns 57,236 shares of the company’s stock valued at $500,000 after buying an additional 21,634 shares during the period. Summit Trail Advisors LLC grew its stake in shares of 10x Genomics by 251.1% in the 1st quarter. Summit Trail Advisors LLC now owns 36,039 shares of the company’s stock valued at $315,000 after buying an additional 25,775 shares during the period. Finally, Teacher Retirement System of Texas acquired a new stake in shares of 10x Genomics in the 1st quarter valued at about $123,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TXG has been the subject of several research reports. Wall Street Zen upgraded 10x Genomics from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Zacks Research upgraded 10x Genomics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Barclays restated an “overweight” rating and issued a $15.00 target price (up from $13.00) on shares of 10x Genomics in a research note on Friday, August 8th. Morgan Stanley cut their price target on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Tuesday, August 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $13.65.

Insider Activity at 10x Genomics

In related news, CFO Adam Taich sold 22,315 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the transaction, the chief financial officer owned 309,273 shares in the company, valued at approximately $4,264,874.67. This represents a 6.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Serge Saxonov sold 9,348 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the transaction, the chief executive officer owned 945,892 shares in the company, valued at approximately $13,043,850.68. The trade was a 0.98% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,149 shares of company stock worth $539,865. Insiders own 9.39% of the company’s stock.

10x Genomics Stock Up 3.1%

Shares of NASDAQ TXG opened at $13.77 on Friday. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $18.21. The stock’s 50 day moving average price is $12.87 and its 200-day moving average price is $11.33. The company has a market capitalization of $1.71 billion, a PE ratio of -19.67 and a beta of 2.05.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. During the same quarter in the prior year, the business earned ($0.32) earnings per share. 10x Genomics’s revenue for the quarter was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, research analysts expect that 10x Genomics will post -1.43 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.